Australia's Mesoblast Chief Elated Israel's Teva To Be 20 Percent Owner
This article was originally published in PharmAsia News
Executive Summary
Mesoblast of Australia is elated by the purchase of U.S.-based Cephalon by Israel's Teva Pharmaceutical Industries